Gastric cancer

Abstract Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especia...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2009-08, Vol.71 (2), p.127-164
Main Authors: Catalano, Vincenzo, Labianca, Roberto, Beretta, Giordano D, Gatta, Gemma, de Braud, Filippo, Van Cutsem, Eric
Format: Article
Language:English
Subjects:
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Gastric cancer
Gastroenterology. Liver. Pancreas. Abdomen
Hematology, Oncology and Palliative Medicine
Humans
Management
Medical sciences
Neoplasm Staging
Palliative Care
Pharmacology. Drug treatments
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Analysis
Treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especially in more advanced stages. Surgery is the mainstay of treatment of this disease. At least D1 resection combined to removal of a minimum of 15 lymph nodes should be recommended. In recent years, important advances have been achieved in the adjuvant setting, where survival benefits were demonstrated by perioperative chemotherapy and postoperative chemoradiotherapy. In advanced disease, patient prognosis remains very poor with median survival times rarely approaching 1 year. In this setting, palliation of symptoms, rather than cure, is the primary goal of patient management. No standard regimens have yet been established worldwide. Recent clinical trials have demonstrated major improvements, which include the development of orally administered fluoropyrimidines (capecitabine, S-1), and the addition of new drugs such as docetaxel, irinotecan, oxaliplatin. This review summarizes the most important recommendations for the management of patients with gastric cancer.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2009.01.004